Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

KW-2871 enters malignant melanoma study

June 13, 2002

GVAX cancer vaccines highlighted at the ASGT meeting

June 12, 2002

ING-1 suitable for further evaluation according to initial human study

June 7, 2002

Promising phase I results with ISF-154 lead to initiation of phase II trial in CLL

June 7, 2002

Virulizin granted fast track designation in pancreatic cancer

June 6, 2002

Weekly administration of WX-G250 is safe and effective against renal cell carcinoma

June 5, 2002

MDX-010 induces tumor reductions in phase I trials in metastatic melanoma and prostate cancer

June 5, 2002

Delay in PSA and clinical progression of prostate cancer achieved using Prostvac

June 3, 2002

Final analysis of phase III data for Zamyl in AML

June 3, 2002

Second phase II trial for GVAX pancreatic cancer vaccine

May 31, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 11, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026